CURRENT TOPIC

Nutritional management of the infant with cystic fibrosis

M R Green, E Buchanan, L T Weaver

The Children's Hospital, Leicester Royal Infirmary, Leicester
M R Green

Department of Dietetics, Royal Hospital for Sick Children, Glasgow
E Buchanan

University Department of Human Nutrition, Yorkhill Hospitals, Glasgow
L T Weaver

Correspondence to:
Dr L T Weaver, University Department of Human Nutrition, Royal Hospital for Sick Children, Yorkhill, Glasgow G3 8SJ.

Identification of the infant with cystic fibrosis by neonatal screening of blood immunoreactive trypsin has been undertaken in some regions for many years,[1] and molecular methods are increasingly being used for the genetic detection of affected children.[2] Several retrospective studies suggest that early detection of cystic fibrosis is beneficial in the long term[3 4]: improved nutritional status,[5] and decreased morbidity from respiratory infection follow treatment that begins soon after diagnosis.[6]

Detection of the cystic fibrosis gene[7] has not only made possible genetic screening of affected fetuses and carriers,[8] but may also offer a cure for this disease.[9] While exciting therapeutic prospects, such as manipulation of the abnormal gene product[10] and pharmacological interventions to correct defective chloride transport across epithelial cell membranes[11] are explored, there remains the challenge of caring for the infant with cystic fibrosis identified in the neonatal period. The major objectives of treatment are to prevent pulmonary infection and to ensure optimal growth and nutrition. Physiotherapy from diagnosis, a full course of immunisations, and prophylactic oral flucloxacillin[6] are all indicated.

In this review we discuss the nutritional management of the infant with cystic fibrosis identified soon after birth, in the light of our growing understanding of the pathophysiology of the disease in early life. There are three major reasons why nutrition of the infant with cystic fibrosis requires special attention (table 1).

Exocrine pancreatic insufficiency

The acinar to connective tissue ratio of the pancreas of the fetus with cystic fibrosis decreases progressively during the last trimester of pregnancy.[12] This is probably due to the primary defect of chloride impermeability of the exocrine pancreatic ductules[13]:

acinar secretions become dry, proteinaceous, and viscous causing ductular obstruction. Inspissated secretions lead to ductular dilatation and formation of periductular fibrous connective tissue. Destruction of acinar tissue also begins well before birth, documented by a serial decline in blood immunoreactive trypsin values, and most children with cystic fibrosis have negligible levels by school age.[14] At birth the infant with cystic fibrosis has 50% less active secretory exocrine tissue than the healthy neonate. Although its functional reserve capacity is large, and clinically significant steatorrhoea and azotorrhoea do not occur until more than 90% of lipase and trypsin output is lost,[15] most infants with cystic fibrosis have measurable exocrine pancreatic deficiency.[16]

Deficiency of pancreatic lipase, colipase, phospholipase A2, bicarbonate, and bile salt secretion all contribute to fat malabsorption, and the infant with cystic fibrosis therefore relies largely on lingual lipase, an enzyme active at low pH. Preduodenal lipase activity in cystic fibrosis represents up to 90% of the total lipolytic activity in the acidic duodenal environment.[17] Pancreatic lipase, trypsin, and amylase are all inactivated below pH 5, and at this pH conjugated bile acids precipitate in aqueous solution and fatty acids are protonated prematurely, together further impairing micellar formation.

Immature hepatobiliary function, with diminished bile acid synthesis and a small bile acid pool tend toward 'physiological cholestasis' in the newborn.[18] Obstruction of the pancreaticobiliary system by inspissated secretions rarely occur in infancy,[19] but there may be increased intraluminal sequestration of bile acids in cystic fibrosis due to adsorption to dietary residues,[20] with a consequent further reduction in the size of the bile acid pool. A predominance of glycine rather than taurine conjugates (the former preferentially precipitated at acidic pH and significantly absorbed in the proximal small intestine),[21] exacerbates the deficient micellar solubilisation of fat. Moreover while both amino acids may be lost in the stool, only glycine can be endogenously synthesised.

Small intestinal enteropathy

The small intestine may also be affected in cystic fibrosis, further contributing to poor

Table 1 Physiological disturbances leading to special nutritional requirements for infants with cystic fibrosis

Pancreas and liver	Pancreatic insufficiency from birth resulting in diminished enzyme secretion with maldigestion of fat, complex carbohydrate, and protein. Intraluminal sequestration of bile acids leading to reduction in bile salt pool and deficient solubilisation of fat
Small intestine	Defect in active and passive absorption related to abnormalities of absorptive cell membrane structure and function
Energy metabolism	Increased energy expenditure related to basic defect and respiratory infection

nutrition. Deficiencies of phospholipid and essential fatty acids may reduce the integrity of enterocyte cell membranes and impair the absorptive phase of fat assimilation.[22] Alteration of mucous glycoprotein structure and mucosal hydrolase and transport systems may affect the absorption of carbohydrates and amino acids. Decreased lactase activity, and altered passive permeability[23] may further contribute to deficient small intestinal function, accounting for nutrient losses as high as 50% of intake.[24]

Around 20% of infants with cystic fibrosis present with meconium ileus[25] and a few with atresias or perforation.[26] Although not all undergo gastrointestinal surgery, enteral nutrition may not be possible for prolonged periods and some infants require total parenteral nutrition, which in itself may diminish normal exocrine pancreatic secretory function and gastrointestinal function. Coeliac disease and gastro-oesophageal reflux are reported more commonly in cystic fibrosis,[27] and as well as pancreatic insufficiency, compromise of small intestinal function further contributes to malabsorption and poor nutrition in cystic fibrosis.

Increased energy needs

Measurement of energy expenditure using indirect calorimetry and the doubly labelled water method suggests that infants with cystic fibrosis have an increased energy expenditure compared with normal infants of the same age, even in the absence of respiratory disease.[28 29] The cystic fibrosis transmembrane conductance regulator (CFTR), the putative gene product, contains multiple sites capable of protein kinase phosphorylation and ATP binding suggesting that ATP hydrolysis may be involved directly in the presumed transport function of CFTR and contribute to enhanced energy utilisation. The commonest cystic fibrosis gene mutation (δF508) results in the loss of a phenylalanine residue in the first nucleotide binding fold of the CFTR, and there is evidence that infants with two mutations within nucleotide binding folds have a greater energy defect than those who are heterozygous in this respect, or carry other mutations outside the nucleotide binding folds.[30] Such an intrinsic defect in energy metabolism, at a molecular level, has important implications for the nutritional management of infants with cystic fibrosis, and implies that they may require greater energy intakes to achieve normal growth.

Although many infants have signs of respiratory disease at diagnosis,[6 25] persistent pulmonary infection is uncommon in infancy. If the child is tachypnoeic or has other signs of respiratory distress he or she will be less able to achieve an adequate nutrient intake. This is in addition to the work involved in combating repeated microbial infections, mounting an inflammatory response, and replacing the protein and energy lost in sputum and faeces.[31 32]

Nutritional management

A dietitian should work with the paediatrician to make a careful assessment of nutritional status at diagnosis. A clinical nurse specialist can also provide invaluable support and advice to the family at home during this time.[33] Although many infants are underweight at diagnosis, most achieve normal weight for age by 12 months.[6] Clinical evaluation comprises measurement of body weight, length, head circumference, mid upper arm circumference and skinfold thicknesses, all of which should be plotted on appropriate centile charts. Chest radiography should be performed and blood taken for full blood count and film, baseline liver function tests, and serum proteins. More specific laboratory nutritional assessment should include quantitative fat balance studies. In centres where this is not possible the stool fat output can be assessed using the 'steatocrit' method or by faecal fat microscopy,[34] and stool chymotrypsin can be measured as an index of exocrine pancreatic function.[35] Vitamin and mineral deficiencies can occur.[36] Serum concentrations of the fat soluble vitamins A, E, and D should be measured at diagnosis and thereafter annually. Trace elements are not routinely measured but this may be necessary in the severely malnourished child.

The choice of milk for the infant with cystic fibrosis depends on a number of factors, which include an understanding of pathophysiology of exocrine pancreatic insufficiency.

HUMAN MILK

Breast feeding has been widely advocated for the baby with cystic fibrosis who is clinically well. It has several theoretical advantages: human milk has an optimal essential amino acid and fatty acid content, and the presence of taurine is particularly important because of its role in bile acid conjugation.[21] In addition human milk contains a range of protective factors, trophic factors, and digestive enzymes including amylase[37] and lipase that may compensate for diminished pancreatic secretion.[38] Fat and carbohydrate absorption are more efficient from human milk than from artificial formulas.[39]

Human milk, however, has a lower protein content than infant formulas and exclusive breast feeding has been associated with failure to thrive, and in a few cases with hypoproteinaemia, oedema, anaemia, and electrolyte depletion.[40] In spite of these potential but rare problems breast feeding should be encouraged as long as adequate intake is ensured.

INFANT FORMULA

Infants with cystic fibrosis who are not breast fed can thrive satisfactorily on normal infant formula[41] with adequate pancreatic enzyme replacement therapy (see below). If infants fail to gain weight satisfactorily on infant formulas alone, glucose polymers such as Maxijul (Scientific Hospital Supplies, SHS) Polycal (Cow and Gate), or Caloreen (Clintec) can be added to the feed. Glucose polymers have a low osmolality and are added in 1 g/100 ml increments to provide a total of 12 g carbohydrate/100 ml of feed. If further energy

Table 2   Recommendations for nutritional management for infants with cystic fibrosis, in conjunction with pancreatic enzyme supplements

Energy	120–150% of DRV	Feeds can be supplemented with glucose polymers
Protein	100% DRV	
Fat	45% of total energy requirements	Feeds can be supplemented with fat emulsions
Vitamin A	4000–8000 IU	} Given orally as a water miscible preparation
Vitamin D	400–800 IU	} (Abidec (Warner Lambert) 0·6 ml/day)
Vitamin E	50–100 mg	
Vitamin K	Not routinely given	
Water soluble vitamins	Not routinely given	
Minerals	Not routinely given	

DRV=dietary reference values.

supplementation is required, long chain lipid emulsions, such as Calogen (SHS), can be added to provide a total of 5 g fat/100 ml feed. Duocal (SHS), a combined fat and carbohydrate supplement, may be used as an alternative energy supplement which can be added to infant formula. Many infants with cystic fibrosis consume large volumes of infant formula (150–200 ml/kg or more),[41] despite apparently adequate enzyme replacement.

Infants who require surgery for meconium ileus may develop a temporary disaccharide intolerance and protein hydrolysate milks such as Pregestimil (Bristol Myers), Nutramigen (Bristol Myers), Peptijunior (Cow and Gate), and Prejomin (Milupa) can be used.[42] Pancreatic enzymes are still required with protein hydrolysate formulas, even though they contain a higher proportion of their fat as medium chain triglycerides.

Occasionally, a modular feed, such as comminuted chicken (Cow and Gate), with additional carbohydrate, fat, vitamins and minerals, may be necessary for infants who have undergone major surgery and fail to tolerate hydrolysed protein formulas.

PANCREATIC ENZYME SUPPLEMENTS
Neither pancreatin powders nor enteric coated microsphere enzyme preparations are designed for administration with human milk. Pancreatin powders should be mixed with a little expressed breast milk and given at the beginning of each feed. Enzyme on the infant's lips may not only cause skin irritation, but also irritation of mother's nipple. Enteric coated preparations can be mixed either with expressed breast milk or formula, or with fruit puree and given from a spoon. They should never be added to feeds. The advantage of the enteric coated microspheres is that their enzyme contents are protected from hydrolysis in the stomach.[43]

VITAMIN SUPPLEMENTS
Fat soluble vitamins A, D, and E should be given routinely from the time of diagnosis, as depletion of these micronutrients is detectable within a few months of birth.[44] Clinical signs of vitamin A deficiency include hyperkeratosis, failure to thrive, anaemia, and hepatosplenomegaly. Depressed serum concentrations may also be due to deficiency of retinol binding protein itself. Bone demineralisation can occur in children with cystic fibrosis but rickets is

rarely seen, probably because dermal synthesis of vitamin D accounts for more than 80% of normal requirements.[45] Vitamin E is a powerful antioxidant and haemolytic anaemia has been reported in newly diagnosed infants.[46] Prolonged deficiency is associated with a peripheral neuropathy, although in cystic fibrosis this is usually associated with advanced hepatic disease. Clinically obvious vitamin K deficiency, presenting as haemorrhagic disease, is unusual in infants with cystic fibrosis and supplementation is not routinely undertaken unless there is evidence of liver disease.[19]

Fat soluble vitamins should be provided from time of diagnosis at concentrations of at least twice dietary reference values: vitamin A 4000–8000 IU, vitamin D 400–800 IU, and vitamin E 50–100 mg/day.[47] Because there is no single vitamin preparation to provide all three vitamins in satisfactory quantities, multivitamin preparations with additional vitamin E are usually prescribed (table 2).

Infants most at risk from fat soluble vitamin deficiency are those with poorly controlled malabsorption, poor dietary compliance, liver disease, bowel resection, or after late diagnosis. The water soluble vitamins (B group and C) are not usually deficient but may be given as part of a multivitamin supplement.

MINERALS AND TRACE ELEMENTS
Iron absorption is usually normal in infancy, and iron supplements are not routinely prescribed in the first year. Low serum concentrations of trace elements, including selenium and zinc, have been reported,[34] but supplementation is not recommended routinely in early life.

ESSENTIAL FATTY ACIDS
Essential fatty acids are required for neurodevelopment and membrane synthesis and function and may be malabsorbed in the infant with steatorrhoea, and contribute to the enteropathy of cystic fibrosis (see earlier). Signs of essential fatty acid deficiency (desquamation, poor wound healing, thrombocytopenia) are rarely seen, and supplementation beyond that recommended for inclusion in modern standard formulas is probably unnecessary in infancy.

ENERGY REQUIREMENTS
The finding of a raised resting and total energy expenditure in infants with cystic fibrosis, and excessive faecal losses, suggest that total energy requirements should be 120–150% of the dietary reference values. Despite improved pancreatic enzyme replacement therapy, faecal energy losses can be as high as 10–20% of energy intake. Most infants who ingest normal volumes of milk for their age will receive adequate protein for growth. Infants who do not thrive on human milk or infant formula will require energy supplemented feeds as discussed earlier.

Other clinical problems and weaning

It is unusual for the infant with cystic fibrosis to require nasogastric or intravenous feeding. However, infants with cystic fibrosis who have undergone gastrointestinal surgery may initially need total parenteral nutrition using standard solutions, and those with extensive ileal resection may require parenteral vitamin B_{12} replacement. Infants who have persistent diarrhoea or fail to gain weight despite seemingly adequate diet and pancreatic enzyme supplementation should undergo jejunal biopsy to exclude coeliac disease. This may occasionally also reveal partial or complete deficiency of lactase activity. Gastro-oesophageal reflux occurs more frequently in cystic fibrosis.[27] Treatment includes thickening of feeds, Gaviscon (Reckitt and Colman), and sometimes cisapride.

The infant with cystic fibrosis is often dissatisfied with breast milk or infant formula alone and solids should be introduced at 3 months of age to ensure an optimal intake of energy and protein. Parents are encouraged to give a normal to high fat intake to ensure adequate growth.

Conclusions

Identification of the infant with cystic fibrosis in early life offers the opportunity to optimise nutrition from diagnosis. Although our understanding of the basic defect in cystic fibrosis, and the way in which it affects the clinical expression and natural history of the disease, is still incomplete, enough is known about the ontogeny of the pancreatic defect, and of the factors contributing to enhanced nutritional requirements, to treat early infancy as a critical period in the life of the infant newly diagnosed with cystic fibrosis. Optimising the nutritional status,[48] and anticipating his or her nutritional needs during childhood, has been shown to reduce morbidity and improve outcome of this chronic disease.[49] There is no doubt that improvement of nutrition in early life, along with other interventions, should play a central part in the management of the infant newly diagnosed with cystic fibrosis.[50]

1 Heeley AF, Heeley ME, King DN, Kuzemko JA, Walsh MP. Screening for cystic fibrosis by dried blood spot trypsin assay. *Arch Dis Child* 1982; **57:** 18–21.
2 Burn J, Magnay D, Claber O, Curtis A. Population screening in cystic fibrosis. *J R Soc Med* 1993; **86** (suppl 20): 2–6.
3 Wilcken B, Chalmers G. Reduced morbidity in patients with cystic fibrosis detected by neonatal screening. *Lancet* 1985; i: 1319–21.
4 Dankert-Roelse JE, te Meerman GJ, Martijn A, ten Kate LP, Knol K. Survival and clinical outcome in patients with cystic fibrosis, with or without neonatal screening. *J Pediatr* 1981; **114:** 362–7.
5 Greer R, Shepherd RW, Cleghorn G, Bowling FG, Holt T. Evaluation of growth and changes in body composition following neonatal diagnosis of cystic fibrosis. *J Pediatr Gastroenterol Nutr* 1991; **13:** 52–8.
6 Weaver LT, Green MR, Nicholson K, *et al.* Prognosis in cystic fibrosis treated with continuous flucloxacillin from the neonatal period. *Arch Dis Child* 1994; **70:** 84–9.
7 Rommens JM, Iannuzzi MC, Kerem B, *et al.* Identification of the cystic fibrosis gene: chromosome walking and jumping. *Science* 1989; **245:** 1059–65.
8 Mennie ME, Gilfillan A, Compton M, *et al.* Prenatal screening for cystic fibrosis. *Lancet* 1992; **340:** 214–6.
9 Flotte TR. Prospects for virus based gene therapy for cystic fibrosis. *J Bioenerg Biomembr* 1993; **25:** 37–42.
10 Hyde S, Gill DR, Higgins CF, *et al.* Correction of the ion transport defect in cystic fibrosis transgenic mice by gene therapy. *Nature* 1993; **362:** 250–5.
11 Knowles MR, Church NL, Waltner WE, *et al.* A study of aerosolised amiloride for the treatment of lung disease in cystic fibrosis. *N Engl J Med* 1990; **362:** 1189–94.
12 Sturgess JM. Structural and developmental abnormalities of the exocrine pancreas in cystic fibrosis. *J Pediatr Gastroenterol Nutr* 1984; **3** (suppl 1): S55–66.
13 Quinton PM. Chloride impermeability in cystic fibrosis. *Nature* 1983; **301:** 421–3.
14 Heeley AF, Bangert SK. The neonatal detection of cystic fibrosis by measurement of immunoreactive trypsin in blood. *Ann Clin Biochem* 1992; **29:** 361–76.
15 Di Magno EP, Go VLW, Summerskill WHJ. Relations between enzyme outputs and malabsorption in severe pancreatic insufficiency. *N Engl J Med* 1973; **288:** 813–5.
16 Waters DL, Dorney RN, Gaskin KJ, Gruca MA, O'Halloran M, Wilcken B. Pancreatic function in infants identified as having cystic fibrosis in a neonatal screening programme. *N Engl J Med* 1990; **322:** 303–8.
17 Dutta SK, Hamosh M, Abrams CK, Hamosh P. Quantitative estimation of lingual lipase activity in the upper small intestine in patients with pancreatic insufficiency. *Gastroenterology* 1982; **82:** 1047.
18 Watkins JB, Szczepanik P, Gould JP, Klein P, Lester R. Bile salt metabolism in the human premature infant. *Gastroenterology* 1975; **69:** 706–13.
19 Scott-Jupp R, Lama M, Tanner MS. Prevalence of liver disease in cystic fibrosis. *Arch Dis Child* 1991; **66:** 698–701.
20 Leroy C, Lepage G, Morin CL, Bertrand JM, Dufour-Larue O, Roy CC. Effect of dietary fat and residues on fecal loss of sterols and on their microbial degradation in cystic fibrosis. *Dig Dis Sci* 1986; **31:** 911–8.
21 Roy CC, Weber AM, Morin CL, *et al.* Abnormal biliary lipid composition in cystic fibrosis. Effect of pancreatic enzymes. *N Engl J Med* 1977; **282:** 1301–5.
22 Innis SM. Plasma and red blood cell fatty acid values as indexes of essential fatty acids in the developing organs of infants fed with milk formulas. *J Pediatr* 1992; **120** (suppl): S78–86.
23 Murphy MS, Sheldon W, Brunetto A, *et al.* Active and passive sugar absorption in pancreatic insufficiency. *J Pediatr Gastroenterol Nutr* 1989; **8:** 189–94.
24 Shmerling DH, Forrer JCW, Prader A. Fecal fat and nitrogen in healthy children and in children with malabsorption or maldigestion. *Pediatrics* 1970; **46:** 690–5.
25 Green MR, Weaver LT, Heeley AF, *et al.* Cystic fibrosis identified by neonatal screening: incidence, genotype and early natural history. *Arch Dis Child* 1993; **68:** 464–7.
26 King A, Mueller RF, Heeley AF, Roberton NRC. Diagnosis of cystic fibrosis in premature infants. *Pediatr Res* 1986; **20:** 536–41.
27 Scott RB, O'Loughlin EB, Gall DG. Gastro-esophageal reflux in cystic fibrosis. *J Pediatr* 1985; **106:** 223–7.
28 Girardet JP, Tounian P, Sardet A, *et al.* Resting energy expenditure in infants with cystic fibrosis. *J Pediatr Gastroenterol Nutr* 1994; **18:** 214–9.
29 Shepherd RW, Holt TL, Vasques-Velasquez L, Coward WA, Prentice A, Lucas A. Increased energy expenditure in young children with cystic fibrosis. *Lancet* 1988; i: 1300–3.
30 O'Rawe AO, Dodge JA, Redmond AOB, McIntosh I, Brock DJH. Gene/energy interaction in cystic fibrosis. *Lancet* 1990; **335:** 552–3.
31 Murphy JL, Wootton SA, Bond SA, Jackson AA. Energy content of stools in normal healthy controls and patients with cystic fibrosis. *Arch Dis Child* 1991; **66:** 495–500.
32 Morrison JM, O'Rawe A, McCracken KJ, Redmond AOB, Dodge JA. Energy intakes and losses in cystic fibrosis. *Journal of Human Nutrition and Dietetics* 1994; **7:** 39–46.
33 Nicholson K. The CF nurse specialist and neonatal screening: child care and research in Each Anglia. In: David TJ, ed. *Role of the cystic fibrosis nurse specialist.* Abingdon: Medicine Group, 1992: 32–8.
34 Walters MP, Kelleher J, Gilbert J, Littlewood JM. Clinical monitoring of steatorrhoea in cystic fibrosis. *Arch Dis Child* 1990; **65:** 99–102.
35 Brown GA, Sule D, Williams J, Puntis JWL, Booth IW, McNeish AS. Faecal chymotrypsin: a reliable index of exocrine pancreatic function. *Arch Dis Child* 1988; **63:** 785–9.
36 Reardon M, Hammond K, Accurso F, *et al.* Nutritional deficiencies exist before two months of age in some infants with cystic fibrosis identified by screening test. *J Pediatr* 1984; **105:** 271–4.
37 Lindberg T, Skude G. Amylase in human milk. *Pediatrics* 1982; **70:** 235–8.
38 Jensen RG, Clark RM, de Jong FA, Hamosh M, Liao TH, Mehta NR. The lipolytic triad: human lingual, breast milk, and pancreatic lipases. Physiological implications of their characteristics in digestion of dietary fats. *J Pediatr Gastroenterol Nutr* 1982; **1:** 242–55.
39 Alemi B, Hamosh M, Scanlon JW, Salzman-Mann C, Hamosh P. Fat digestion in very low-birth-weight infants: effect of addition of human milk to low-birth-weight formula. *Pediatrics* 1981; **68:** 484–9.
40 Laughlin JJ, Brady MS, Eigen H. Changing feeding trends

as a cause of electrolyte depletion in infants with cystic fibrosis. *Pediatrics* 1981; **68:** 203–7.

41 Holliday K, Allen J. Growth of human milk-fed and formula-fed infants with cystic fibrosis. *J Pediatr* 1991; **118:** 77–9.

42 Farrell P, Mischler E, Sonder S, Palta M. Predigested formula for infants with cystic fibrosis. *J Am Diet Assoc* 1987; **87:** 1353–6.

43 Stead RJ, Skypala I, Hodson ME, Batten JC. Enteric coated microspheres of pancreatin in the treatment of cystic fibrosis: comparison with a standard enteric coated preparation. *Thorax* 1987; **42:** 533–7.

44 Sokol R, Reardon M, Accurso F, *et al.* Fat soluble vitamin status during the first year of life in infants with cystic fibrosis identified by screening of newborns. *Am J Clin Nutr* 1989; **50:** 1064–71.

45 Hahn TJ, Squires AE, Halstead LR, *et al.* Reduced serum 25-hydroxy vitamin D concentration and disordered

mineral metabolism in patients with cystic fibrosis. *J Pediatr* 1979; **94:** 38–42.

46 Farrell PM, Bieri JG, Fratantoni JF, Wood RE, di Sant'Agnese PA. The occurrence and effects of human vitamin E deficiency. A study in patients with cystic fibrosis. *J Clin Invest* 1977; **60:** 233–41.

47 Rayner RM. Fat soluble vitamins in cystic fibrosis. *Proc Nutr Soc* 1991; **51:** 245–50.

48 Simmonds EJ, Wall CR, Wolfe SP, Littlewood JM. A review of infant feeding practices at a regional cystic fibrosis unit. *Journal of Human Nutrition and Dietetics* 1992; **7:** 31–8.

49 Dalzell AM, Shepherd RW, Dean B, Cleghorn GY, Holt TL, Francis PJ. Nutritional rehabilitation in cystic fibrosis: a 5 year follow-up study. *J Pediatr Gastroenterol Nutr* 1992; **15:** 141–5.

50 Green MR, Weaver LT. Early and late outcome of CF screening. *J R Soc Med* 1994; **87** (suppl 21): 5–10.